Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Small Cell Lung Cancer Recurrent × Clear all

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 226 Neoplasms 151 Colorectal Neoplasms 107 Stomach Neoplasms 95 Uterine Cervical Neoplasms 83 Carcinoma, Non-Small-Cell Lung 77 Prostatic Neoplasms 74 Lung Neoplasms 66 Carcinoma, Hepatocellular 65 Rectal Neoplasms 48 Ovarian Neoplasms 48 Pancreatic Neoplasms 45 Esophageal Neoplasms 44 Colonic Neoplasms 41 Neoplasm Metastasis 35 Recurrence 33 Multiple Myeloma 32 Motor Activity 32 Endometrial Neoplasms 32 Head and Neck Neoplasms 31 Lymphoma 30 Thyroid Neoplasms 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 27 Polycystic Ovary Syndrome 27 Melanoma 27 Urinary Bladder Neoplasms 26 Small Cell Lung Carcinoma 24 Leukemia, Myeloid, Acute 24 Lymphoma, Non-Hodgkin 23 Nasopharyngeal Carcinoma 20

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262454 2022-04-06

Atezolizumab

National Cancer Center, Korea

Phase 2 Unknown

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡